Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04724980
Other study ID # 210013
Secondary ID 21-C-0013
Status Active, not recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date March 16, 2021
Est. completion date June 2, 2026

Study information

Verified date October 2023
Source Precigen, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 1/2 study in patients with a Recurrent Respiratory Papillomatosis (RRP) disease burden that requires repeated surgical procedures for management. RRP is a rare disease caused by the human papillomavirus (HPV). Participants with a pathologically confirmed diagnosis of papilloma and a clinical diagnosis of RRP will be screened for this protocol.


Description:

This is a nonrandomized, Phase 1/2 safety and tolerability study. The safety and tolerability of PRGN-2012 will be assessed following two different dose levels during the Phase 1 dose escalation trial. In the Phase 2 portion of the study, treatment with PRGN-2012 at the recommended Phase 2 dose (RP2D) will be used to determine safety and efficacy of PRGN-2012.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 38
Est. completion date June 2, 2026
Est. primary completion date June 2, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility INCLUSION CRITERIA: - Age 18 years and older - Clinical diagnosis of RRP - Histological diagnosis of papilloma confirmed by pathology report from a CLIA-certified (or comparable) laboratory - Presence of laryngotracheal papillomas with or without pulmonary RRP - A history of 3 or more interventions in the last 12 months for control of RRP - Clinical performance status of ECOG of 0-1 - Willing to undergo endoscopic evaluation and operative interventions with biopsies in compliance with this protocol - No systemic therapy for RRP for at least 3 half-lives of the prior drug(s). A 30-day washout is required for systemic bevacizumab treatment - Participants who have received prior immunotherapy for RRP are permitted - Participants must have adequate organ and marrow function as defined below: - Sexually active subjects (men and women) of reproductive potential must agree to use two methods of contraception: one highly effective and one other effective method throughout vaccine treatment and for at least 120 days after vaccine treatment. Highly effective methods are defined as: Intrauterine device (IUD), hormonal (birth control pills, injections, implants), tubal ligation, and partner's vasectomy; other effective methods are defined as a latex condom, diaphragm, and cervical cap. - Seronegative for hepatitis B antigen, positive hepatitis B tests can be further evaluated by confirmatory tests (Hep B DNA quant, HBV viral load), and if confirmatory tests are negative, the participant can be enrolled. - Seronegative for hepatitis C antibody unless antigen negative. If the hepatitis C antibody test is positive, then participants must be tested for the presence of antigen by Hep C RNA quant, HCV viral load, and be HCV RNA negative - All participants must have the ability to understand and willingness to sign a written informed consent EXCLUSION CRITERIA: - A history of surgical debridement of papillomas such that in the opinion of the study team a participant is unlikely to be able to safely have a six-week interval between clinically indicated interventions. - History of significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (greater than or equal to New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication. - Any severe acute or chronic medical or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior, liver disease, lung disease (with the exception of what is specified in the inclusion criteria) , or laboratory abnormalities that, in the opinion of the investigators, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results and in the judgment of the investigator, would make the participant inappropriate for entry into this study. Participants with mild to moderate asthma or chronic obstructive pulmonary disease (COPD) well controlled with oral or inhaled medications are permitted to enroll. - Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled, topical intranasal or intro-ocular steroids, and adrenal replacement doses <10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. - Participants who are receiving any other investigational agents - Persisting toxicity related to prior therapy of Grade >1 NCI-CTCAE v 5.0; however, alopecia, sensory neuropathy Grade less than or equal to 2 or other Grade less than or equal to 2 AEs not constituting a safety risk based on investigator's judgment are acceptable. - Known alcohol or drug abuse. - Participant, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study. - History of allergy to study drug components. - Pregnant women are excluded from this study because PRGN-2012 is an agent with unknown potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with PRGN-2012, breastfeeding should be discontinued if the mother is treated with PRGN-2012. These potential risks may also apply to other agents used in this study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PRGN-2012
In the Phase 1, 3+3 dose escalation clinical trial evaluating PRGN-2012 at two dose levels (1x10^11 and 5x10^11 particle units (PU)) administered as adjuvant therapy prior to standard-of-care debulking surgery. In the Phase 2 segment, PRGN-2012 is evaluated at the RP2D.

Locations

Country Name City State
United States National Institutes of Health Clinical Center Bethesda Maryland

Sponsors (2)

Lead Sponsor Collaborator
Precigen, Inc National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determine the percentage of subjects with a complete response following treatment with PRGN-2012 A complete response is defined as no requirement for surgical intervention in the 12 months after treatment 1 year
Primary Determine the incidence of dose limiting toxicities to evaluate safety and identify RP2D of PRGN-2012 The incidence of dose limiting toxicities in Phase 1 will be reported per dose level. The dose level at which less than or equal to 1 out of 6 patients experience DLT will be identified as a RP2D. 28 days
Secondary Safety of PRGN 2012 at RP2D Systemic toxicity will be assessed through the capture of Treatment Emergent Adverse Events ( TEAEs) at Phase 1 and Phase 2 patients. The severity of the TEAEs will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 scale. 1 year
Secondary Immune Responses Change in HPV-specific T cells post-treatment compared to baseline 1 year
Secondary Change in RRP Staging Assessment Scores Over Time Absolute and percentage change from baseline in Derkay score over time following initiation of PRGN-2012 treatment 1 year
Secondary Change in Vocal Function Scores over Time Absolute and percentage change from baseline in VHI-10 score over time following initiation of PRGN-2012 treatment 1 year
Secondary Time to recurrence of papillomatous disease after completion of treatment Time to recurrence of papillomatous disease after completion of treatment will be recorded. Time from completion of treatment to first surgery will be assessed. 1 year
Secondary Percentage of subjects with reduction in number of surgeries after completion of treatment The number of surgeries in the 12 months post-treatment will be compared to the number of surgeries in the 12 months pre-treatment to identify subjects that have a reduction in the number of surgeries. 1 year
Secondary Number of surgery during the 12 months pre and 12 months post treatment The number of surgeries in the 12 months post-treatment will be compared to the number of surgeries in the 12 months pre-treatment. 1 year
Secondary Overall Response Rate Determine the percentage of subjects with at least a 50% decrease in the number of surgeries during the 12 month period following completion of PRGN-2012 treatment as compared to the number of surgeries during the 12 months prior to PRGN-2012 treatment initiation. 1 year
Secondary Rate of pulmonary RRP partial response in participants with pulmonary disease The fraction of participants with a pulmonary RRP partial response will be reported in all treated pulmonary participants. 1 year
Secondary Rate of pulmonary RRP complete response in participants with pulmonary disease The fraction of participants with a pulmonary RRP complete response will be reported in all treated pulmonary participants. 1 year
See also
  Status Clinical Trial Phase
Completed NCT00973856 - Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands N/A
Active, not recruiting NCT05580341 - Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 Phase 3
Completed NCT06399341 - Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR).
Recruiting NCT03548740 - Diversity Analysis of Vaginal Microbiota on Women With High-risk Human Papillomavirus Infection
Completed NCT00092547 - A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) Phase 3
Completed NCT00157950 - Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED) Phase 3
Recruiting NCT00365729 - Viral Load Determination and Biomarkers of High Risk Human Papillomavirus (HPV) - Types in HIV-positive Men N/A
Completed NCT03584308 - Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal Phase 2
Not yet recruiting NCT04115787 - Conservative Management in Patients Diagnosed With Grade 2 or Grade 3 CIN
Completed NCT04072913 - Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix N/A
Completed NCT00549250 - Human Papillomavirus 6/11 in the Lower Airway of Neonates N/A
Recruiting NCT04694495 - HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study
Completed NCT06439433 - ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection Phase 2
Completed NCT00380367 - Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029) Phase 3
Completed NCT01894425 - Human Papillomavirus and Rate of Pregnancy Achieved Via Medically Assisted Procreation N/A
Completed NCT00685412 - Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3 Phase 1
Completed NCT00365716 - Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED) Phase 2
Completed NCT04772534 - Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066) Phase 3
Completed NCT05119855 - Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076) Phase 3
Completed NCT03487549 - Cantharidin and Occlusion in Verruca Epithelium Phase 2